When they partner away development and distribution rights to their products, biotech companies often retain manufacturing rights to provide a source of revenue. But having the rights may not always be worth the effort, as Cypress Bioscience Inc. and Molecular Biosystems Inc. concluded in transferring the manufacturing for marketed products to their partners.

Both companies said that they do not need the processes for projects outside the scope of their partnerships.